Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 339 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: thiazolidinedione Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women

NCT01748994
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 6, 2026, 10:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

NCT00179400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone, Placebo, Pancreatic Clamp Study
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

NCT01432405
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 6, 2026, 10:35 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 6, 2026, 10:35 PM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 6, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

NCT01309854
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone, Drug-drug Interaction, Amount of Pioglitazone in Blood
Interventions
fostamatinib, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Rosiglitazone Effect on Mitochondria and Lipoatrophy

NCT00367744
View directory record Official record
Conditions
HIV Infections
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Inflammation and Insulin Resistance in Rheumatoid Arthritis

NCT00763139
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

NCT01002547
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
pioglitazone-placebo, pioglitazone, Vitamin E, Vitamin E-placebo
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

The Impact of Obesity and Obesity Treatments on Breast Cancer

NCT00933309
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Avandamet
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

NCT00926016
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pioglitazone (Actos)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 6, 2026, 10:35 PM EDT
Recruiting Phase 1 Interventional

SGLT2i, Pioglitazone, and Ketone Production in T2D

NCT07053319
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

NCT01150981
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects

NCT01088919
View directory record Official record
Conditions
Healthy, Pharmacokinetics of ASP1941
Interventions
ASP1941, pioglitazone hydrochloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 4 Interventional

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Vascular Diseases
Interventions
Rosiglitazone, Pioglitazone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

NCT00676338
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, metformin, sitagliptin, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
18
States / cities
Buena Park, California • Los Angeles, California • Valencia, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

NCT00545233
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

NCT00671515
View directory record Official record
Conditions
Depressive Disorder, Major, Metabolic Syndrome X
Interventions
Pioglitazone
Drug
Lead sponsor
Joseph Calabrese, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

NCT00634036
View directory record Official record
Conditions
Asthma
Interventions
pioglitazone, placebo
Drug
Lead sponsor
Fernando Holguin
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

NCT00402909
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Nateglinide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
28 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 6, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

NCT01100619
View directory record Official record
Conditions
Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
Interventions
rosiglitazone, XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 6, 2026, 10:35 PM EDT